ZAI LAB LIMITED (ZLAB) Debt Components
- 2026-06-30: Short-term DebtUSD $238.10M; Short-term Debt, Weighted Average Interest Rate, at Point in Timepure 2.41%.
- 2026-03-31: Short-term DebtUSD $213.82M; Short-term Debt, Weighted Average Interest Rate, at Point in Timepure 2.45%.
- 2025-12-31: Short-term DebtUSD $204.53M; Short-term Debt, Weighted Average Interest Rate, at Point in Timepure 2.55%.
- 2025-09-30: Short-term DebtUSD $203.03M; Short-term Debt, Weighted Average Interest Rate, at Point in Timepure 2.63%.
ZAI LAB LIMITED Debt Components
Filed components and totals, with each concept and unit kept separate. Components can overlap; they are not added together. Missing disclosures remain (m). Original concept pages retain their detailed breakdowns and history.
| Period end | Short-term Debt USD | Short-term Debt, Weighted Average Interest Rate, at Point in Time pure |
|---|---|---|
| 2026-06-30 | $238.10M | 2.41% |
| 2026-03-31 | $213.82M | 2.45% |
| 2025-12-31 | $204.53M | 2.55% |
| 2025-09-30 | $203.03M | 2.63% |
| 2025-06-30 | $174.51M | 2.66% |
| 2025-03-31 | $173.41M | 2.72% |
| 2024-12-31 | $131.71M | 2.88% |
| 2024-09-30 | $112.99M | 3.01% |
| 2024-06-30 | $70.30M | 3.05% |
| 2024-03-31 | $48.27M | 3.10% |
| 2023-12-31 | $0.00 | (m) |
| 2020-06-30 | $4.24M | (m) |
| 2019-12-31 | $6.45M | (m) |
| 2019-09-30 | $6.36M | (m) |
| 2018-12-31 | $3.64M | (m) |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Aurinia Pharmaceuticals Inc. (AUPH) | $2.207B | 7.18 | |
| Prestige Consumer Healthcare Inc. (PBH) | United States | $2.163B | 13.03 |
| OCULAR THERAPEUTIX, INC (OCUL) | United States | $2.159B | -7.15 |
| Viridian Therapeutics, Inc.\DE (VRDN) | United States | $2.342B | -5.38 |
| Mineralys Therapeutics, Inc. (MLYS) | United States | $2.353B | -6.82 |
| Bausch Health Companies Inc. (BHC) | $2.113B | -1.68 | |
| Braveheart Bio, Inc. (BRVE) | United States | $2.106B | |
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| Harmony Biosciences Holdings, Inc. (HRMY) | United States | $2.399B | 11.67 |